FDA Panel Votes to Recommend More Restrictions on Hydrocodone Combos

An FDA advisory panel voted 19–10 Friday to recommend up-scheduling hydrocodone combination products to schedule II controlled substances, a move that would bring tighter restrictions on the opioid painkillers.
Drug Industry Daily